NASDAQ:NEO NeoGenomics (NEO) Stock Price, News & Analysis → Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (From Colonial Metals) (Ad) Free NEO Stock Alerts $15.30 +0.58 (+3.94%) (As of 05/3/2024 ET) Add Compare Share Share Today's Range$14.90▼$15.3950-Day Range$13.42▼$16.2752-Week Range$11.03▼$21.22Volume875,872 shsAverage Volume934,598 shsMarket Capitalization$1.95 billionP/E RatioN/ADividend YieldN/APrice Target$19.78 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get NeoGenomics alerts: Email Address NeoGenomics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.82 Rating ScoreUpside/Downside29.3% Upside$19.78 Price TargetShort InterestBearish5.98% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.26Based on 32 Articles This WeekInsider TradingSelling Shares$38,702 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.20) to ($0.10) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.87 out of 5 starsMedical Sector2353rd out of 5,430 stocksTesting Laboratories Industry1st out of 6 stocks 4.4 Analyst's Opinion Consensus RatingNeoGenomics has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on 9 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageNeoGenomics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.98% of the outstanding shares of NeoGenomics have been sold short.Short Interest Ratio / Days to CoverNeoGenomics has a short interest ratio ("days to cover") of 8.5.Change versus previous monthShort interest in NeoGenomics has recently increased by 5.52%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldNeoGenomics does not currently pay a dividend.Dividend GrowthNeoGenomics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NEO. Previous Next 2.4 News and Social Media Coverage News SentimentNeoGenomics has a news sentiment score of 0.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 32 news articles for NeoGenomics this week, compared to 4 articles on an average week.Search InterestOnly 2 people have searched for NEO on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.MarketBeat Follows7 people have added NeoGenomics to their MarketBeat watchlist in the last 30 days. This is an increase of 75% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, NeoGenomics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $38,702.00 in company stock.Percentage Held by InsidersOnly 1.30% of the stock of NeoGenomics is held by insiders.Percentage Held by Institutions98.50% of the stock of NeoGenomics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for NeoGenomics are expected to grow in the coming year, from ($0.20) to ($0.10) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NeoGenomics is -23.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NeoGenomics is -23.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNeoGenomics has a P/B Ratio of 2.12. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressNever use this word on your phone (FBI could be watching)This report sent a chill down my spine. Turns out, as part of their Jan. 6th investigation, the Feds are flagging Americans who typed these ordinary words as part of their banking transactions...Watch my unredacted video about what I think is coming next right here About NeoGenomics Stock (NASDAQ:NEO)NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.Read More NEO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NEO Stock News HeadlinesMay 3, 2024 | americanbankingnews.comNeoGenomics (NASDAQ:NEO) Price Target Cut to $20.00May 2, 2024 | markets.businessinsider.comBuy Rating Affirmed for NeoGenomics Amid Strong Q1 Performance and Growth ProspectsMay 4, 2024 | Colonial Metals (Ad)The asset beating inflation by 4x"Trump Loophole" Beats Inflation? Inflation has been out of control for years. Forcing you to work longer and harder for more money that is worth less. By using the "Trump Loophole", you can use a special retirement account to buy gold — and other precious metals — without taxes or penalties.May 2, 2024 | finance.yahoo.comNeoGenomics, Inc. (NASDAQ:NEO) Q1 2024 Earnings Call TranscriptMay 2, 2024 | finance.yahoo.comNeoGenomics First Quarter 2024 Earnings: Revenues Beat Expectations, EPS LagsMay 1, 2024 | au.finance.yahoo.comQ1 2024 Neogenomics Inc Earnings CallMay 1, 2024 | msn.comNeoGenomics in Fort Myers and Herc in Bonita announce earnings. How did they do?May 1, 2024 | finance.yahoo.comNeoGenomics Inc (NEO) Q1 2024 Earnings Call Transcript Highlights: Strategic Growth and ...May 4, 2024 | Colonial Metals (Ad)The asset beating inflation by 4x"Trump Loophole" Beats Inflation? Inflation has been out of control for years. Forcing you to work longer and harder for more money that is worth less. By using the "Trump Loophole", you can use a special retirement account to buy gold — and other precious metals — without taxes or penalties.May 1, 2024 | americanbankingnews.comNeoGenomics (NASDAQ:NEO) Given New $19.00 Price Target at Needham & Company LLCMay 1, 2024 | americanbankingnews.comNeoGenomics (NASDAQ:NEO) Stock Price Down 7.7% on Analyst DowngradeApril 30, 2024 | msn.comNEO Stock Earnings: NeoGenomics Beats EPS, Beats Revenue for Q1 2024April 30, 2024 | finance.yahoo.comNeoGenomics Q1 2024 Earnings: Revenue Surpasses Estimates, Net Loss NarrowsApril 30, 2024 | msn.comNeoGenomics beats top-line and bottom-line estimates; reaffirms FY24 outlookApril 30, 2024 | businesswire.comNeoGenomics Reports First Quarter 2024 ResultsApril 29, 2024 | markets.businessinsider.comNeogenomics earnings: here's what Wall Street expectsApril 29, 2024 | msn.comNeoGenomics Q1 2024 Earnings PreviewApril 29, 2024 | benzinga.comNeoGenomics Stock (NASDAQ:NEO), Short Interest ReportApril 22, 2024 | markets.businessinsider.comLeerink Partners Keeps Their Buy Rating on NeoGenomics (NEO)April 18, 2024 | businesswire.comNeoGenomics Announces Senior Leadership PromotionsApril 9, 2024 | businesswire.comNeoGenomics to Report First Quarter 2024 Financial Results on April 30, 2024March 27, 2024 | businesswire.comNeoGenomics Showcases Commitment to Transforming Cancer Patient Care at AACR 2024 Annual MeetingMarch 21, 2024 | nasdaq.comCommit To Purchase NeoGenomics At $10, Earn 9.1% Annualized Using OptionsMarch 20, 2024 | msn.comNeogenomics Pokes Up On Unveiling ESG ReportMarch 20, 2024 | businesswire.comNeoGenomics Releases Inaugural Environmental, Social, and Governance (ESG) ReportMarch 14, 2024 | barrons.comNeoGenomics Inc.March 11, 2024 | au.finance.yahoo.comOmics Lab Services Market Report 2024 - Innovations in Genomics and Big Data AnalyticsSee More Headlines Receive NEO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NeoGenomics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/20/2024Today5/03/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Testing laboratories Sub-IndustryN/A Current SymbolNASDAQ:NEO CUSIPN/A CIK1077183 Webwww.neogenomics.com Phone(239) 768-0600Fax239-690-4237Employees2,100Year Founded2002Price Target and Rating Average Stock Price Target$19.78 High Stock Price Target$26.00 Low Stock Price Target$17.00 Potential Upside/Downside+29.3%Consensus RatingModerate Buy Rating Score (0-4)2.82 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($0.66) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-87,970,000.00 Net Margins-13.79% Pretax Margin-14.91% Return on Equity-3.54% Return on Assets-1.99% Debt Debt-to-Equity Ratio0.58 Current Ratio7.48 Quick Ratio5.95 Sales & Book Value Annual Sales$610.66 million Price / Sales3.20 Cash Flow$0.31 per share Price / Cash Flow49.45 Book Value$7.23 per share Price / Book2.12Miscellaneous Outstanding Shares127,712,000Free Float126,006,000Market Cap$1.95 billion OptionableOptionable Beta1.12 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Christopher Michael Smith BSc (Age 61)CEO & Director Comp: $2.86MMr. Jeffrey S. Sherman M.B.A. (Age 58)Chief Financial Officer Comp: $1.17MMr. Vishal Sikri (Age 48)President of Advanced Diagnostics Comp: $1.08MMs. Melody Harris Esq. (Age 57)J.D., President & COO of Informatics Comp: $1.4MMr. Warren Stone (Age 51)Chief Commercial Officer Comp: $1.42MMs. Kendra SweeneyVice President of Investor Relations & CommunicationsMs. Alicia Olivo (Age 40)Executive VP of Business Development, General Counsel & Corporate Secretary Mr. Hutan Hashemi J.D. (Age 45)Chief Compliance Officer Dr. Derek Lyle M.D.Chief Medical OfficerMr. Gary PassmanChief Culture OfficerMore ExecutivesKey CompetitorsCatalyst PharmaceuticalsNASDAQ:CPRXMyriad GeneticsNASDAQ:MYGNSchrödingerNASDAQ:SDGRSyndax PharmaceuticalsNASDAQ:SNDXHarmony BiosciencesNASDAQ:HRMYView All CompetitorsInsiders & InstitutionsJennison Associates LLCBought 460,071 shares on 5/2/2024Ownership: 0.824%BNP Paribas Financial MarketsSold 15,606 shares on 5/1/2024Ownership: 0.067%Allspring Global Investments Holdings LLCBought 1,791 shares on 4/30/2024Ownership: 0.017%Principal Financial Group Inc.Sold 2,242 shares on 4/29/2024Ownership: 0.519%Yousif Capital Management LLCSold 7,508 shares on 4/26/2024Ownership: 0.045%View All Insider TransactionsView All Institutional Transactions NEO Stock Analysis - Frequently Asked Questions Should I buy or sell NeoGenomics stock right now? 11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for NeoGenomics in the last twelve months. There are currently 2 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" NEO shares. View NEO analyst ratings or view top-rated stocks. What is NeoGenomics' stock price target for 2024? 11 brokerages have issued 12 month price targets for NeoGenomics' shares. Their NEO share price targets range from $17.00 to $26.00. On average, they predict the company's stock price to reach $19.78 in the next twelve months. This suggests a possible upside of 29.3% from the stock's current price. View analysts price targets for NEO or view top-rated stocks among Wall Street analysts. How have NEO shares performed in 2024? NeoGenomics' stock was trading at $16.18 at the beginning of the year. Since then, NEO stock has decreased by 5.4% and is now trading at $15.30. View the best growth stocks for 2024 here. When is NeoGenomics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our NEO earnings forecast. How were NeoGenomics' earnings last quarter? NeoGenomics, Inc. (NASDAQ:NEO) released its quarterly earnings results on Tuesday, February, 20th. The medical research company reported ($0.02) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.07) by $0.05. The medical research company had revenue of $155.55 million for the quarter, compared to analysts' expectations of $152.90 million. NeoGenomics had a negative trailing twelve-month return on equity of 3.54% and a negative net margin of 13.79%. What ETFs hold NeoGenomics' stock? ETFs with the largest weight of NeoGenomics (NASDAQ:NEO) stock in their portfolio include SPDR S&P Health Care Services ETF (XHS), Invesco S&P SmallCap Health Care ETF (PSCH), WisdomTree BioRevolution Fund (WDNA), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG) and iShares U.S. Healthcare Providers ETF (IHF).SPDR S&P 600 Small Cap ETF (SLY). What guidance has NeoGenomics issued on next quarter's earnings? NeoGenomics updated its FY 2024 earnings guidance on Tuesday, April, 30th. The company provided EPS guidance of 0.000-0.040 for the period, compared to the consensus EPS estimate of -0.010. The company issued revenue guidance of $650.0 million-$660.0 million, compared to the consensus revenue estimate of $654.6 million. What is Douglas M. VanOort's approval rating as NeoGenomics' CEO? 116 employees have rated NeoGenomics Chief Executive Officer Douglas M. VanOort on Glassdoor.com. Douglas M. VanOort has an approval rating of 98% among the company's employees. This puts Douglas M. VanOort in the top 20% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of NeoGenomics own? Based on aggregate information from My MarketBeat watchlists, some companies that other NeoGenomics investors own include Marvell Technology (MRVL), NVIDIA (NVDA), Alibaba Group (BABA), Block (SQ), Inseego (INSG), PayPal (PYPL), Micron Technology (MU), Invitae (NVTA), CRISPR Therapeutics (CRSP) and AbbVie (ABBV). Who are NeoGenomics' major shareholders? NeoGenomics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Jennison Associates LLC (0.82%), Principal Financial Group Inc. (0.52%), Oak Family Advisors LLC (0.08%), BNP Paribas Financial Markets (0.07%), Yousif Capital Management LLC (0.05%) and Silverberg Bernstein Capital Management LLC (0.02%). Insiders that own company stock include Alicia C Olivo, Bruce K Crowther, Douglas Matthew Brown, George Cardoza, Kathryn B Mckenzie, Mark Mallon, Robert J Shovlin and William Bonello. View institutional ownership trends. How do I buy shares of NeoGenomics? Shares of NEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does NeoGenomics have any subsidiaries? The following companies are subsidiares of NeoGenomics: Clarient Inc., Clarient Diagnostic Services Inc, Clarient Inc, Cynogen Inc., GE Medical Holding AB., Genesis Acquisition Holding Corp, Genesis Acquisition Holdings Corp., Genoptix, Genoptix Inc., Inivata Inc., Inivata Limited, Inivata Limited., Minuet Diagnostics Inc., NeoGenomics Bioinformatics Inc., NeoGenomics Europe SA, NeoGenomics Foundation Inc, NeoGenomics Laboratories Inc, NeoGenomics Singapore Pte. Ltd, Path Labs LLC, Suzhou NeoGenomics Pharmaceutical Research Co. Limited, Trapelo Health, and Trapelo Health LLC.Read More This page (NASDAQ:NEO) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldElon to Transform U.S. Economy? Porter & CompanyGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchAutomatic Income (from home)Awesomely, LLCClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsCould Your Accounts Be Frozen?Allegiance GoldFW: 234x GainWeiss RatingsStock-Picking AI Predicts #1 Stock of 2024Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeoGenomics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
